Managing Candidemia JEANNE FORRESTER, PHARMD, BCPS PGY2 INFECTIOUS DISEASES PHARMACY RESIDENT MEDICAL UNIVERSITY OF SOUTH CAROLINA.

Slides:



Advertisements
Similar presentations
GOOD MORNING! Thursday, February 2, CSF Shunts Used in the setting of hydrocephalus to divert CSF to another part of the body for absorption Proximal.
Advertisements

Infection Control: IV Drug Administration
From Guidelines to Bedside: Clinical Case Scenario Approach Mazen Kherallah, MD, FCCP.
Dr. Kouros Aghazade Shahid Beheshti Medical University
Identify patient at risk for Candida infection Major risk factors includeOther risk factors include Previous bacterial infection and therapy Tunneled venous.
Fungi Plant-like organisms that lack chlorophyll 1 of the 5 Kingdoms
Fungal Infection in the ICU
ANTIFUNGAL DRUGS Fungal infections (mycoses) can be both superficial and systemic. Superficial infections (Oral and vulvovaginal candidiasis, Dermatophytosis,
Initial Antifungal Therapy for Critical Ill Patients When and Which ? 林口長庚 胸腔內科 林鴻銓 Lin, Horng-Chyuan Division of Pulmonary Infectious & Immunological.
Antifungal Drugs I. Humans and fungi share a common biosynthetic pathway for sterols from squalene (via squalene 2,3 epoxidase and other enzymes) to lanosterol.
Diagnosis and Treatment of Invasive Candida Infections in Neonates and Children AHD October 11, 2012 Rupesh Chawla MD MSc FRCPC Clinical Assistant Professor.
Clinical Scenario  A 42 year old white female was admitted to the hospital with hematemesis and melena. The patient had a history of cirrhosis with ascites.
Febrile Neutropenia Allison Ferrara, MD Princeton Baptist Medical Center Baptist Health Systems Alabama.
Empiric Antifungal Therapy in the ICU
Esophageal Candidiasis in Patients with AIDS. Case 32-year-old male with AIDS CD4 50 cells/mm3 Reports severe pain and difficulty swallowing “It feels.
Rex summary of updated IDSA Candidiasis guidelines.ppt IDSA Candidiasis Guidelines John H. Rex, MD Adjunct Professor of Medicine; University of Texas.
Cryptococcal Meningitis in Patients with AIDS. Clinical Case 30-year-old male with AIDS CD4 25 cells/mm3 Gradual increasing headache for past five days.
Eunice Huang, MD, MS APSA Education Day Palm Desert, CA May 22, 2011
Candida Fungemia Risks and Therapy Hail M. Al-Abdely, M.D. Associate Consultant King Faisal Specialist Hospital.
Antimicrobial Stewardship Program JMH House staff Orientation 2012 Lilian Abbo, MD Assistant Professor Clinical Infectious Diseases Laura Smith, PharmD.
Antibiotic overuse and misuse in long term care Shira Doron, MD Assistant Professor of Medicine Division of Geographic Medicine and Infectious Diseases.
Combination Antifungal Therapy By Amy Barnett, Doctor of Pharmacy Candidate University of Florida College of Pharmacy.
Invasive Candida Infections in the ICU B. Guery Lille Infectious Diseases Summit: Fungal Series.
LINE INFECTIONS DIAGNOSIS AND TREATMENT HOSPITAL MEDICINE CURRICULUM PAMELA PRIDE MD,FHM MEDICAL UNIVERSITY OF SOUTH CAROLINA MAY 21, 2013.
Katherine Gerrald, PharmD Candidate 1 ; Anne Hishon, PharmD Candidate 1 ; P. Brandon Bookstaver, PharmD, BCPS 2 1 University of South Carolina, College.
Fungus: SICU Bradley J. Phillips, M.D. Burn-Trauma-ICU Adults & Pediatrics.
Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Mucocutaneous Candidiasis Slide Set Prepared.
Shira Doron, MD Assistant Professor of Medicine
Which drugs?. Mode of action of antifungals ergosterol polyenes e.g. amphotericin B polyenes azoles e.g. fluconazole azoles nucleosides e.g. 5-flucytosine.
Selection of an optimal antifungal for treatment of invasive aspergillosis: susceptibility/resistance, adverse reactions, drug interactions John Bennett,
Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Aspergillosis Slide Set Prepared by the AETC.
Antimicrobial treatment for Systemic Candidiasis.
1 Helen Whamond Boucher, M.D. Senior Associate Director Clinical Development Pfizer Global Research & Development.
Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Cryptococcosis Slide Set Prepared by the AETC.
Diversity of Fungi and Fungal Infections
Caspofungin prophylaxis vs placebo, followed by preemptive Tx for invasive candidiasis (IC) in ICU pts: MSG-01 study Multi-centre, double-blind, phase.
ANTIFUNGAL DRUGS PHARM 514 Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington
Fungal endophthalmitis
Dr C Sriruttan Clinical Microbiology & Infectious Disease /11/20161 Principles & Approach.
Hot Topics in Infectious Diseases Giuseppe Nunnari.
Outline of the Presentation
Antifungal Therapy in Immunocompromised Patient. Immunocompromised  An Immunocompromised host is a patient who does not have the ability to respond normally.
Risk Factors for Candida dubliniensis Bloodstream Infections Katherine Veltman, B.S., Peggy L. Carver, Pharm.D, FCCP The University of Michigan Health.
Prepared by the AETC National Coordinating Resource Center based on recommendations from the CDC, National Institutes of Health, and HIV Medicine Association/Infectious.
Prepared by the AETC National Coordinating Resource Center based on recommendations from the CDC, National Institutes of Health, and HIV Medicine Association/Infectious.
Prepared by the AETC National Coordinating Resource Center based on recommendations from the CDC, National Institutes of Health, and HIV Medicine Association/Infectious.
Medicine II Homework January 6, 2010 Subsection B4 Facilitator: Remedios F. Coronel, M.D.
Date of download: 9/17/2016 From: Empirical Anti-Candida Therapy among Selected Patients in the Intensive Care Unit: A Cost- Effectiveness Analysis Ann.
Fungal infection of urinary tract 신장내과 R4 최선영. Opportunistic fungal pathogen in urinary tract  Candida : most prevalent and pathogenic fungi UTI –hematogenous.
Fungal Peritonitis (FP) Constantinos J. Stefanidis “P. and A. Kyriakou” Children’s Hospital Athens, Greece.
HAP and VAP Guidelines Update
Fungal Infections and Antifungals in ICU
Antifungal drugs Lec Dr. Naza M. Ali
University Health Network
Antifungal prophylaxis in liver transplantation
Management of Urinary Tract Infections Renal Block
Management of Urinary Tract Infections Renal Block
LEISHMANIASIS Dr.Abdul latif Mahesar Dept.of medical pharmacology
Diversity of Fungi and Fungal Infections
Universidad Militar Nueva Granada, School of Medicine
Clinical Case Conference #5
Utilizing the Candida Score to Identify Patients at Increased Risk for
Staten Island University Hospital, Staten Island, New York, USA
Fungal endophthalmitis
This slide set is meant to be used as an adjunct resource to the Medscape program titled “Managing Invasive Candidiasis: A Systematic Approach” by Thomas.
Intra-Abdominal Candidiasis, Candida peritonitis
Anidulafungin for the treatment of invasive candidiasis
بنام خداوند جان و خرد بنام خداوند جان و خرد.
Pharmacokinetic/Pharmacodynamic Dosing
Presentation transcript:

Managing Candidemia JEANNE FORRESTER, PHARMD, BCPS PGY2 INFECTIOUS DISEASES PHARMACY RESIDENT MEDICAL UNIVERSITY OF SOUTH CAROLINA

Objectives Identify risk factors for candidemia Describe appropriate pharmacologic management for patients with candidemia

Candida species Candida are yeast (fungi) found throughout the environment Also commonly isolated from the GI tract, sputum, female genital tract, and urine (especially catheterized patients) However, rarely considered contaminant when isolated from sterile site Edwards JE. Candida species. In: Mandell, Douglas, and Bennett’s Prinicples and Practice of Infectious Diseases, 8 th ed.

Candidemia Candidemia refers to the presence of Candida in blood ◦One of the most common causes of healthcare-associated bloodstream infections Symptoms may range fever to sepsis Mortality: 10 to 47% Antifungal therapy should be initiated as soon as possible after positive culture Pappas PG, et al. Clin Infect Dis. 2016;62(4):e1.

Risk Factors for Candidemia Broad-Spectrum Antibiotics Central Venous Catheters Parenteral Nutrition Renal Replacement Therapy NeutropeniaImmunosuppression Edwards JE. Candida species. In: Mandell, Douglas, and Bennett’s Prinicples and Practice of Infectious Diseases, 8 th ed.

Treatment of Candidemia Echinocandin Non- Neutropenic: fluconazole Neutropenic: liposomal amphotericin B First-Line: Alternatives: Pappas PG, et al. Clin Infect Dis. 2016;62(4):e1.

Antifungal Mechanisms of Action Katzung BG, et al. Basic & Clinical Pharmacology, 11 th edition.

Echinocandins First-line therapy for candidemic patients per 2016 IDSA Candidiasis Guidelines Specific agents ◦Caspofungin: 70 mg x 1, then 50 mg daily ◦Micafungin: 100 mg daily ◦Anidulafungin: 200 mg x 1, then 100 mg daily Poor penetration into CNS, eye, and urinary tract Pappas PG, et al. Clin Infect Dis. 2016;62(4):e1. Lexi-Comp Online.

Fluconazole Azole susceptibility should be performed on Candida blood isolates Transition to fluconazole (IV or PO) from echinocandin if susceptible and clinically stable ◦Dosing: 800 mg (12 mg/kg) load followed by 400 mg (6 mg/kg) daily ◦For C. glabrata, 800 mg (12 mg/kg) daily preferred Pappas PG, et al. Clin Infect Dis. 2016;62(4):e1. Lexi-Comp Online.

Amphotericin B Lipid formulation ◦↑Cost ↓Toxicity Dosing of liposomal amphotericin B ◦3-5 mg/kg IV daily Adverse effects ◦Nephrotoxicity, electrolyte wasting, infusion reaction ◦“Salt loading” to prevent nephrotoxicity ◦Pre-treatment if infusion reaction occurs Pappas PG, et al. Clin Infect Dis. 2016;62(4):e1. Lexi-Comp Online. Image: ambisome.com

Non-Pharmacologic Management Blood cultures should be done at least every other day until clear ◦Duration of therapy: 2 weeks from first negative blood culture if no complications ◦Neutropenic patients: treat until symptoms and neutropenia have resolved (minimum of 2 weeks after clearance of Candida) Remove central lines if possible Non-neutropenic patients should have dilated ophthalmological exam within the first-week of diagnosis ◦Neutropenic patients: should be done during the first week of recovery from neutropenia Pappas PG, et al. Clin Infect Dis. 2016;62(4):e1.

Conclusions Candidemia is a common healthcare-associated infection Prompt treatment with appropriate antifungal therapy, initially an echinocandin in most cases, is vital to clinical success

Managing Candidemia JEANNE FORRESTER, PHARMD, BCPS PGY2 INFECTIOUS DISEASES PHARMACY RESIDENT MEDICAL UNIVERSITY OF SOUTH CAROLINA